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The Na/K-ATPase has been extensively studied, but it is only
recently that its role as a scaffolding and signaling protein has
been identified. It has been identified that cardiotonic steroids
(CTS) such as digitalis mediate signal transduction through the
Na/K-ATPase in a process found to result in the generation of
reactive oxygen species (ROS). As these ROS also appear
capable of initiating this signal cascade, a feed forward
amplification process has been postulated and subsequently
implicated in some disease pathways including uremic
cardiomyopathy.
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Introduction
The Na/K-ATPase enzyme (EC 3.6.3.9.), or ‘sodium
pump’ was first identified by Skou on the crab nerve in
1957 [1]. Besides its transportation of ions, in the late
1990s, Dr. Zijian Xie and our research group discovered a
scaffolding and signaling function for the Na/K-ATPase,
where the Na/K-ATPase/Src complex acts as a unique
receptor for cardiotonic steroids (CTS). This signaling
pathway appears to be involved a number of clinical
disorders including cardiovascular diseases and hyperten-
sion, salt balance, renal diseases, diabetes and other
metabolic diseases, as well as neurological disorders
[2,3]. Moreover, the alteration of signaling receptor func-
tion is also seen in hypertension, cardiac hypertrophy,
ischemia/reperfusion injury, cancer, and tissue fibrosis.
Therefore, this enzyme assumes an increasing impor-
tance for researchers and clinicians [4].
Structure and pumping function of the
Na/K-ATPase
Structurally, Na/K-ATPase primarily consists of three
subunits denoted by a, b, and g, with only the a and
b subunits necessary for ion pumping. The catalytic a
subunit contains binding sites for the cations (Na+ and
K+), ATP and cardiotonic steroids (CTS) such as ouabain
[5]. The b subunit is also essential for pump function, and
it appears to stabilize the a subunit conformation as well
as chaperone the delivery of the a/b complex to the
plasma membrane. In some tissues, a third subunit, g
subunit (FXYD protein) may help to regulate sodium
pump activity [6,7]. The Na/K-ATPase a subunit with
11 transmembrane domains has 4 isoforms. The a1 iso-
form is found in all cells, a2 and a3 isoforms are mainly
expressed in skeletal muscle, neuronal tissue, and cardiac
myocytes. The a4 isoform is in testis and regulates sperm
motility.
The structure–function relationships in Na/K-ATPase
were extensively studied in the later portions of the
20th century and has received new attention due to
the recently recognized Na/K-ATPase scaffolding and
signaling functions which we will discuss further [8,9].
The alteration between two major conformational states
is responsible for pumping of ions. In E1 (Na+-form), the
cation-binding sites have high affinity for Na+ and face
the cytoplasm. In E2 (K+-form), the cation-binding sites
have high affinity for K and face the extracellular side
[9,10]. Functionally, the Na/K-ATPase a subunit has
3 cytoplasmic A (actuator), N (nucleotide binding) and
P (phosphorylation) domains. During the ion pumping
cycle, the relative positions of these domains change as
they also do in response to binding CTS [10].
Third factor
It was clear to renal physiologists and nephrologists that
changes in glomerular filtration rate (factor 1) and miner-
alocorticoids (factor 2) could not explain natriuretic
responses to acute or chronic expansion of blood volume
[11]. This point was first demonstrated in 1961 in a classic
paper by de Wardener and colleagues [12]. Natriuresis
induced by saline infusion occurred even if renal perfu-
sion pressure and glomerular filtration rate and aldoste-
rone concentrations were prevented from changing. This
so called ‘third factor,’ which we now understand is (are)
CTS, was proposed by Bricker and colleagues to be an
inhibitor of the Na/K-ATPase and, as such, produced
natriuresis by inhibiting Na reabsorption in the kidney
[13]. However, doubt as to the validity of circulating Na/
K-ATPase inhibitors developed during the 1980s and
1990s because of inconsistencies in the reported results.
In particular, prevailing CTS assays were based on cross-
reactivity of CTS with antibodies to digoxin. The most
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important inconsistency was that digitalis did not appear
to be natriuretic in normal subjects, something one would
expect in a candidate natriuretic substance [14]. Also,
atrial (and brain) natriuretic peptide(s) were discovered
and found to be natriuretic [15–19]. Undoubtedly, these
points, detracted focus from the study of CTS. However,
enthusiasm was renewed in the recent past for the fol-
lowing reasons. First, several CTS have been isolated
from experimental animals and humans and chemically
characterized. Specifically, marinobufagenin (MBG) as
well as telecinobufagin (TCB) have been isolated from
plasma and urine [20]. Ouabain has also been identified
although there is still some debate as to whether this is
ouabain or something distinct which also reacts to anti-
ouabain antibodies [21,22]. The concentrations of oua-
bain (or ouabain like compound) and MBG appear to be
in the range of 2–30  1010 M in humans, depending on
whether disease is present [2,3,23]. Plasma levels of TCB
and bufalin are less well defined at present.
Ionic model for Na/K-ATPase signaling
The concept proposed by Bricker and others was that
third factor or cardiotonic steroids acted like digitalis and
inhibited the enzymatic, ion pumping function of the Na/
K-ATPase. The effects on sodium transport by the kid-
ney seemed obvious in that clearly a failure to pump
sodium out of epithelial cells would decrease net sodium
reabsorption and effect natriuresis. Coupling the Na/K-
ATPase to the Na/Ca exchanger, cardiac and smooth
muscle relevance of these substances also seemed very
clear in that subtle increases in cytosolic sodium would
have amplified effects on cytosolic calcium, effecting
changes in contractility in the heart as well as contractile
tone in smooth muscle cells. The concept is illustrated in
Figure 1.
Although we will explore an alternate hypothesis for the
much of the remainder of this review, it must be said that
this ionic model may explain some of the effects of
digitalis and other cardiotonic steroids previously charac-
terized as third factor. However, for reasons we will
discuss below, certain discrepancies provoked scientists
in our group, in particular Dr. Zijian Xie, to consider and
elaborate a very different mechanism by which these
cardiotonic steroids signal through the Na/K-ATPase.
Xie model of Na/K-ATPase signaling
The Xie model for the Na/K-ATPase signaling function
was derived from difficulties explaining signaling with the
ionic model along with experimental observations regard-
ing reactive oxygen species (ROS) and tyrosine kinase
activities being critical to such signaling. This model
proposed that the caveolar Na/K-ATPase alpha1 subunit
serves as a negative regulator of Src, and that during
conformational changes in alpha1 induced by CTS or
oxidation, Src is allowed to become active and trigger a
signal cascade which involves the generation of reactive
oxygen species (ROS). This model is shown schematical-
ly in Figure 2, and in our admittedly biased opinion
constitutes an important advance in our understanding
of sodium pump signaling.
Problems with ionic model
Although the ionic model makes some predictions con-
sistent with the observed pharmacology of Na/K-ATPase
inhibitors, in general the concentrations of such inhibitors
exceed by orders of magnitude those concentrations
achieved in physiologically relevant models and clinical
therapy. Although there is still some debate about this, it
is generally accepted that endogenous cardiotonic ster-
oids circulate at concentrations ranging from 1010 to
108 M concentrations and pharmacologic treatment with
digitalis compounds achieves concentrations of approxi-
mately 1–2  109 M [2]. In mice and rats used for many
experiments, the IC50 for the a1 subunit approximates
105 M meaning that no detectable inhibition is seen
with these lower concentrations. Even in humans which
have a much more sensitive a1 subunit, the IC50 is
approximately 107 M suggesting that these compounds
might have relatively little effect. More importantly,
changes in bulk cytosolic sodium are essentially impossi-
ble to detect with existing methods. Although these
methods are not ideal and cannot identify sodium con-
centration changes in cytosolic subregions, it is still con-
cerning. Perhaps of greater concern, sodium ionophores
44 Cardiovascular and renal
Figure 1
2K+
3Na
+
Na+
Ca2+
Na+/Ca2+
Exc hanger
[Ca2+]
P PContraction
/Relaxation
Ca2
+
P
CTS Inhib its  Pump  Activi ty
[Na+]
-
PKC
[K+]
Current Opinion in Pharmacology
A schematic illustrating the proposed ionic consequences of Na/K-
ATPase inhibition. Note that such inhibition would predict increases in
cytosolic sodium (Na+) which, through Na/Ca exchange could increase
cytosolic calcium (Ca2+) concentration ([Ca2+]. Decreases in cytosolic
potassium (K+) would change the membrane potential, favoring more
Ca2+ entry, further increasing cytosolic [Ca2+]. This would potentially
activate phosphokinase C (PKC) and other Ca2+ dependent proteins,
which in turn, would have a number of downstream effects.
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which can produce measurable changes in bulk cytosolic
sodium do not appear to produce physiological changes
similar to those produced by cardiotonic steroids [2,3].
Evidence for tyrosine kinase signaling
In the late 1990s, Dr. Xie and colleagues observed that in
neonatal cardiac myocytes, ouabain caused increases in
reactive oxygen species (ROS) measured with CMDCF
[24]. These increases in ROS could be demonstrated even
when cytosolic calcium was maintained low by removal of
extracellular calcium [25]. It was further noted that some of
the downstream effects of ouabain, specifically those on
gene expression, calcium cycling and contractility could be
blocked by N-Acetyl Cysteine (NAC) or vitamin E [24–
26]. It was further noted that Ras activation appeared to be
necessary to see increases in ROS [25]. Other studies
determined that interactions between the Na/K-ATPase
and Src appeared to initiate the signal cascade [27,28]. The
a1 subunit of the Na/K-ATPase binds Src and appears to
maintain it in an inactive state. However, binding a CTS
appears to alter the Na/K-ATPase structure allowing Src
became activated which, in turn, trans-activates the
EGFR, and begins the signal cascade which causes
increases in ROS [27–30]. The Na/K-ATPase-Src complex
appears to function similar to a receptor tyrosine kinase.
Downstream activation of PLC, PI(3)K and PKC has also
been established [31–35].
Some of our studies have shed light on the molecular basis
of the Na/K-ATPase a1 subunit-Src interaction. It
appears that there is a critical binding of the tyrosine
kinase domain of Src by a portion of the N domain of the
a1 subunit. Under basal conditions, this binding inhibits
the tyrosine kinase function of Src. We speculate that
conformational changes induced in the Na/K-ATPase by
cardiotonic steroids and/or the specific oxidation of some
amino-acids (vida infra) result in the internalization of this
epitope and the disinhibition of the tyrosine kinase
function of Src with attendant downstream signaling.
This is illustrated in Figure 2. From this speculation,
we have developed a peptide based on this epitope in
combination with a tat leader sequence that allows for
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A schematic illustrating the involvement of cardiotonic steroid (CTS)-induced Na/K-ATPase signal cascade initiated by the Na/K-ATPase mediated
activation of Src tyrosine kinase and subsequent downstream targets eventually leading to the development of reactive oxygen species (ROS).
Specifically, we postulate that in the microdomain of caveolae, the Na/K-ATPase functions as a scaffolding protein, interacting with CTS and
changing conformation so as to active Src. Src then transactivates the EGFR which leads to a signal cascade involving FAK, Shc, Grb2 and SOS
resulting in the generation of ROS which in turn activates additional Na/K-ATPase molecules as well as causes downstream activation of ERK as
well as effects on the nuclear transcription [68]. ERK activation has effects on both L-type channels and possibly the Na/Ca exchanger with net
effect to increase cytosolic Ca2+ in some tissues [35]. Nuclear effects in myocardial tissue include downregulation of SERCA transcription and
translation [69]. Abbreviations: Epidermal growth factor receptor (EGFR); focal adhesion kinase (FAK); Src homology-2 domain containing protein
(Shc); growth factor receptor-bound protein-2 (Grb2); son of sevenless protein (SOS); extracellular-signal-regulated kinase (ERK); sarcoplasmic/
endoplasmic reticulum calcium ATPase (SERCA).
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cellular penetration which we refer to as pNaKtide.
Although pNaKtide has no effect on Na/K-ATPase en-
zymatic or pumping function, it prevents a portion of Src
activation which is usually regulated by the plamalemmal
Na/K-ATPase [36,37].
Oxidant stress in chronic renal failure
Our group and others first proposed that oxidant stress
contributed to the progression of chronic renal failure in
the mid 1980s [38]. The concept which we proposed was
that oxygen consumption by the chronic renal failure
kidney could not be explained by the amount of tubular
sodium transport performed in the setting of a reduced
glomerular filtration rate. Patients with chronic renal
failure consistently demonstrate elevations in circulating
levels of oxidized proteins and byproducts of lipid per-
oxidation. This oxidant stress has been implicated in the
pathogenesis of uremic cardiovascular disease on several
levels [39].
A number of studies utilizing echocardiography have
demonstrated that both left ventricular hypertrophy
(LVH) and diastolic dysfunction (as assessed by left
ventricular, atrial and pulmonary venous doppler flow
studies) are extremely common in end stage renal disease
(ESRD) patients treated with hemodialysis(HD) [40] as
well as patients incident to ESRD [41–43]. In general,
most studies have demonstrated that LVH predicts dia-
stolic dysfunction with some accuracy. Systolic dysfunc-
tion while not uncommon is much less often
demonstrable than diastolic dysfunction and LVH [44].
In experimental chronic renal failure, we have observed
that left ventricular hypertrophy develops quite early and
that impaired myocyte relaxation accompanies the cardi-
ac enlargement. This impaired myocyte relaxation
appears to be associated with a marked downregulation
of SERCA2a mRNA, protein and activity. SERCA2a is
the dominant isoform of the sarcoplasmic reticulum cal-
cium ATPase and is responsible for the rapid reduction in
cytosolic calcium following systole. We have found ex-
cellent correlations between the reduction in SERCA2a
expression and SERCA enzymatic activity as well as
calcium renormalization following electrical stimulation.
We have also found marked abnormalities in cardiac
myocyte calcium concentrations during both systole
and diastole [26,45]. It is unclear at present whether
the abnormalities in SERCA2a expression explain all of
the changes in calcium cycling or active relaxation. Re-
garding passive relaxation, it is very clear that uremic
cardiomyopathy is associated with profound cardiac fibro-
sis, both clinically and in both rats and mice with experi-
mental renal failure [46]. Our group has developed
extensive evidence that blockade of Na/K-ATPase sig-
naling results in amelioration of oxidant stress, down-
regulation of SERCA2a and cardiac fibrosis in these
experimental uremic cardiomyopathy models [47–50].
Na/K-ATPase is a receptor for natriuretic
hormones
Our group has identified that concentrations of CTS
below that necessary to significantly inhibit the enzymatic
function of the Na/K-ATPase directly induce endocytosis
of the Na/K-ATPase in cell lines approximating proximal
tubules, decreasing plasmalemmal Na/K-ATPase expres-
sion and function [51–53]. We have also found that this
ligand-induced endocytosis appears to play a role in
sodium homeostasis in intact animals [54]. We will discuss
some of these mechanistic data below.
In renal proximal tubules, binding of CTS to Na/K-
ATPase stimulates Na/K-ATPase-Src signaling pathway
and reactive oxygen species (ROS) generation, which
induces the redistribution of basalateral a1 subunit of
Na/K-ATPase and apical sodium proton exchanger3
(NHE3). NHE3 (SLC9A3) is responsible for two-third
of filtered sodium and fluid reabsorption as well as main-
tenance and regulation of intravascular volume and blood
pressure [55–57]. Therefore, the downregulation of
NHE3 will decrease transepithelial sodium transporta-
tion from apical membrane into basalateral membrane,
leading to a net increase in urinary sodium excretion
[25,52,58,59–62].
We have begun to address the molecular basis of this
regulation [63]. We have demonstrated that ouabain
increases the carbonylation of a1 Na/K-ATPase in cul-
tured porcine renal proximal tubular LLC-PK1 cells. A
GO-glucose system was used to mimic overall ROS stress
since GO induces a low and sustained generation of H2O2
in the presence of glucose in culture medium [24,25,64].
Like ouabain, the GO-generated ROS were able to acti-
vate Src/ERK and cause redistribution of the Na/K.
Interestingly, the increase in intracellular ROS generated
by the addition of glucose oxidase (GO) to the culture
medium resulted in a nearly identical pattern of protein
carbonylation to that seen with ouabain as well as what
appears to be specific carbonylation of the a1 Na/K-
ATPase. We have further identified that Pro222 and
Thr224 residues of a1 Na/K-ATPase are specifically
carbonylated in response to either exposure to ouabain
or GO-generated ROS. Finally, using well-established
animal models we have demonstrated that high salt
intake is capable of eliciting this oxidative modification
of the Na/K-ATPase as well as the associated signaling
and salt handling events in the renal PT of Sprague
Dawley rats and Dahl-salt resistant (R) but not Dahl
salt-sensitive (S) rats [65]. Overall, our studies show that
ROS are involved in CTS-mediated sodium handling
through Na/K-ATPase signaling in a feed-forward mech-
anism [58,66]. This is illustrated in Figure 3.
The implications of this feed-forward amplification are
profound. One might think of the circulating CTS as the
rheostat on an amplifier which promiscuously allows
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oxidant signals from a variety of signal cascades to be
amplified. This is clearly something which may be rele-
vant beyond the circumstances discussed in this review.
In fact, we have recently observed that the Na/K-ATPase
amplification of such oxidant signals is essential for the
development of an obesity phenotype, and the applica-
tion of pNaKtide, a peptide we designed to bind the
tyrosine kinase domain of Src based on the region of the
Na/K-ATPase a1 subunit N domain which normally does
so, dramatically attenuates this process [67].
Conclusions
The recently discovered oxidant amplification function of
the Na/K-ATPase appears relevant to a number of phys-
iological and pathological processes including renal sodi-
um handling and progressive cardiac fibrosis. Exploitation
of this understanding may allow for modulation of such
processes and the potential development of new clinical
therapies.
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